These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 9793432)

  • 1. [The use of betaserk in patients with cochlear-vestibular disorders].
    Kadymov MI; Poliakova TS; Vladimirova TN
    Vestn Otorinolaringol; 1998; (5):49-50. PubMed ID: 9793432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Betaserk efficiency in cochlear and vestibular disorders in the regional surdocenter].
    Pekaskiĭ SI
    Vestn Otorinolaringol; 2001; (3):61. PubMed ID: 11510053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Betaserk in therapy of cochleovestibular disordes].
    Khrapko NS; Sedykh MI; As'kova LN; Tarasova NV; Velikanov AK; Baryshevskaia LA
    Vestn Otorinolaringol; 2006; (4):59-60. PubMed ID: 17152479
    [No Abstract]   [Full Text] [Related]  

  • 4. [The role of betaserk in combined treatment of neurosensory hypoacusis and vestibulopathy in childhood].
    Chistiakova VR
    Vestn Otorinolaringol; 2004; (2):9-12. PubMed ID: 15111941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Vestibo in the treatment of cochleovestibular disorders].
    Kunel'skaia NL; Levina IuV; Doronina OM; Krasiuk AA; Izotova GN
    Vestn Otorinolaringol; 2008; (6):52-4. PubMed ID: 19209416
    [No Abstract]   [Full Text] [Related]  

  • 6. Fixed combination of cinnarizine and dimenhydrinate versus betahistine dimesylate in the treatment of Ménière's disease: a randomized, double-blind, parallel group clinical study.
    Novotný M; Kostrica R
    Int Tinnitus J; 2002; 8(2):115-23. PubMed ID: 14763223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Trimetazidine versus betahistine in vestibular vertigo. A double blind study].
    Kluyskens P; Lambert P; D'Hooge D
    Ann Otolaryngol Chir Cervicofac; 1990; 107 Suppl 1():11-9. PubMed ID: 2240994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Vestibular disorders in patients with otosclerosis: prevalence, diagnostic and therapeutic options].
    Morozova SV; Dobrotin VE; Kulakova LA; Kaspranskaia GR; Ovchinnikov IuM
    Vestn Otorinolaringol; 2009; (2):20-2. PubMed ID: 19491792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Use of monotreane in the treatment of patients with cochleovestibular disorders].
    Pal'chun VT; Kadymova MI; Kriukov AI
    Vestn Otorinolaringol; 1989; (5):20-2. PubMed ID: 2588407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Report from a Consensus Conference on the treatment of Ménière's disease with betahistine: rationale, methodology and results.
    Casani AP; Guidetti G; Schoenhuber R;
    Acta Otorhinolaryngol Ital; 2018 Oct; 38(5):460-467. PubMed ID: 30498275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rehabilitation of patients with peripheral vestibular disorders].
    Morozova SV; Zaĭtseva OV
    Vestn Otorinolaringol; 2004; (2):59-61. PubMed ID: 15139364
    [No Abstract]   [Full Text] [Related]  

  • 12. The benefits of betahistine or vestibular rehabilitation (Tetrax biofeedback) on the quality of life and fall risk in patients with Ménière's disease.
    Liu JL; Liu JG; Chen XB; Liu YH
    J Laryngol Otol; 2020 Dec; 134(12):1073-1076. PubMed ID: 33280619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Delirium in a 73-year-old man after many years of unwise use of betahistine].
    Hoenders HJ; Wilterdink J
    Ned Tijdschr Geneeskd; 2004 Nov; 148(47):2338-41. PubMed ID: 15587054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the quality of life in patients with vestibular disorders: the role of medical treatments and physical rehabilitation.
    Mira E
    Int J Clin Pract; 2008 Jan; 62(1):109-14. PubMed ID: 17537195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Menière's disease. Current status].
    Darrouzet V; Bouccara D; Bozorg Grayeli A; Couloigner V; Negrevergne M; Sterkers O
    Rev Laryngol Otol Rhinol (Bord); 2001; 122(3):209-15. PubMed ID: 11799866
    [No Abstract]   [Full Text] [Related]  

  • 16. [Betahistine in the treatment of vestibular and coordination disturbances in multiple sclerosis].
    Popova NF; Chugunova MA; Kunel'skaia NL; Shagaev AS; Boĭko AN; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):77-81. PubMed ID: 21916160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hearing function after betahistine therapy in patients with Ménière's disease.
    Seyed Tootoonchi SJ; Ghiasi S; Shadara P; Samani SM; Fouladi DF
    Braz J Otorhinolaryngol; 2016; 82(5):500-6. PubMed ID: 26810620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Betahistine metabolites, aminoethylpyridine, and hydroxyethylpyridine increase cochlear blood flow in guinea pigs in vivo.
    Bertlich M; Ihler F; Sharaf K; Weiss BG; Strupp M; Canis M
    Int J Audiol; 2014 Oct; 53(10):753-9. PubMed ID: 25014609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Betahistine or Cinnarizine for treatment of Meniere's disease.
    Djelilovic-Vranic J; Alajbegovic A; Tiric-Campara M; Volic A; Sarajlic Z; Osmanagic E; Todorovic L; Beslagic O
    Med Arch; 2012; 66(6):396-8. PubMed ID: 23409520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Betahistine dihydrochloride versus flunarizine. A double-blind study on recurrent vertigo with or without cochlear syndrome typical of Menière's disease.
    Fraysse B; Bebear JP; Dubreuil C; Berges C; Dauman R
    Acta Otolaryngol Suppl; 1991; 490():1-10. PubMed ID: 1763646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.